Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.45 |
| ▸ | MERTK | Q12866 | 3/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 9/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.37 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955746 | 0.85 | ALOX15 (0.49) | ADORA3ADORA1MERTKAXLALOX15 | |
| SCHEMBL2946338 | 0.81 | TTK (0.52) | ADORA3TTK | |
| SCHEMBL2951457 | 0.76 | TTK (0.48) | ADORA3ADORA1MERTKAXLTTK | |
| SCHEMBL16013625 | 0.76 | ADORA3 (0.44) | ADORA3ADORA1TTKADORA2A | |
| SCHEMBL4975672 | 0.75 | TTK (0.49) | ADORA3ADORA1MERTKAXLTTK | |
| SCHEMBL4767624 | 0.75 | TTK (0.63) | TTK | |
| SCHEMBL2953219 | 0.75 | ALOX15 (0.39) | ADORA3ADORA1MERTKAXLALOX15 | |
| SCHEMBL2956268 | 0.74 | TTK (0.52) | TTKCLK1CLK2 | |
| SCHEMBL3041055 | 0.74 | TTK (0.61) | ADORA3TTK | |
| SCHEMBL31060929 | 0.74 | ADORA3 (0.68) | ADORA3ADORA1MERTKAXLADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | ADORA3 1744/4885ADORA1 2771/4885MERTK 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.